Do You Qualify for a GLP-1? The 2026 Eligibility Guide

If your BMI is 30 or higher, you meet the core FDA criterion for GLP-1 weight-management therapy — no other condition required. If your BMI is 27 to 29.9, you qualify with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. And in 2026, the paths beyond that baseline have multiplied: new FDA indications for sleep apnea and heart disease, expanded telehealth access, and — for the first time — a Medicare program covering GLP-1s for weight management at a $50 monthly copay.

Eligibility Is a Series of Gates, Not One Question

"Do I qualify?" is really three separate questions. First: do you meet the clinical criteria on the FDA label? Second: will an insurer pay, and under what added conditions? Third: if insurance says no, what does the self-pay route require? People routinely conflate these — and conclude they don't qualify when they actually failed only the second gate, not the first.

This guide walks through each gate as it stands in mid-2026. For the full clinical reference — the complete qualifying-condition table, BMI math, labs, and the evaluation process step by step — see our companion page, Am I Eligible for GLP-1 Medications?. This article focuses on the pathways and what has changed this year.

Gate 1: The FDA Criteria (Broader Than You Think)

For chronic weight management, Wegovy (semaglutide) and Zepbound (tirzepatide) share the same FDA-approved starting criteria for adults, used alongside a reduced-calorie diet and increased physical activity:

• BMI 30 or higher — no additional condition required, or
• BMI 27 or higher plus at least one weight-related condition — the label names examples such as hypertension, type 2 diabetes, and dyslipidemia; in practice clinicians also count conditions like obstructive sleep apnea and cardiovascular disease

To put numbers on it: a person who is 5'6" crosses BMI 30 at roughly 186 pounds, and BMI 27 at roughly 167 pounds. At 5'10", the thresholds are about 209 and 188 pounds. Most people are surprised at how attainable these cutoffs are — which is exactly why more people qualify than commonly think.

These thresholds gate access to medications with substantial clinical effect: semaglutide 2.4 mg produced an average 14.9% body-weight reduction over 68 weeks in the STEP 1 trial, and tirzepatide produced up to 20.9% over 72 weeks in SURMOUNT-1.

Wegovy is also approved for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). BMI has real limitations as a screening tool — it can misclassify muscular people and miss metabolic risk in others — which is one more reason the final call belongs to a clinician looking at your whole picture, not a calculator.

Gate 1b: The Non-Weight Pathways (New and Growing)

A meaningful share of people who start a GLP-1 in 2026 qualify through an indication that is not weight management at all. Three matter most:

Type 2 diabetes — any BMI

Ozempic and Mounjaro (the same molecules as Wegovy and Zepbound, at diabetes dosing) are approved for glycemic control in type 2 diabetes regardless of BMI. If you have a T2D diagnosis, your eligibility conversation runs through diabetes care, and insurance coverage is typically far easier. Our guide to GLP-1s for diabetes vs. weight loss explains how the same drug travels under different names and rules.

Obstructive sleep apnea — Zepbound

In December 2024, the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. If you have a sleep-study-confirmed OSA diagnosis and a BMI of 30 or higher, this is a distinct qualifying pathway — and because OSA is a medically accepted indication, it can also unlock insurance coverage (including Medicare Part D) that a weight-management prescription alone would not.

Cardiovascular risk reduction — Wegovy

In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. For someone with a history of heart attack, stroke, or coronary disease and a BMI of 27 or higher, this indication reframes the eligibility conversation entirely — the prescription is for the heart, with weight loss alongside.

Gate 2: Insurance — Where Most "Denials" Actually Happen

Meeting FDA criteria does not obligate any insurer to pay. Commercial plans commonly layer on prior authorization, step therapy (documented diet attempts or other medications first), higher BMI cutoffs than the label, or outright exclusions of weight-loss drugs. If you've been told you "don't qualify," it's worth checking whether that verdict came from the FDA criteria or from your plan's fine print — they are not the same thing. Our insurance coverage guide covers the appeal and documentation tactics.

The 2026 Medicare change

Medicare Part D has long excluded drugs prescribed for weight loss itself, while covering GLP-1s for medically accepted indications such as type 2 diabetes, obstructive sleep apnea, and MASH (a form of fatty liver disease). That gap is what makes this year's change notable: from July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain GLP-1 medications — CMS lists Foundayo, Wegovy, and the KwikPen formulation of Zepbound — for a $50 monthly copay.

The Bridge is aimed squarely at the people the old rules left out: it is limited to beneficiaries who have not filled a Part D GLP-1 prescription in 2026 and who do not have a diagnosis (like T2D or OSA) that would already qualify them for standard Part D coverage. KFF estimates roughly 3.8 million Part D enrollees met the eligibility criteria as of 2023. If you're on Medicare and were previously told weight-loss medication was simply not covered, 2026 is the year to re-ask the question.

Gate 3: The Self-Pay Telehealth Route

If insurance is a dead end, self-pay telehealth programs apply the same FDA clinical criteria — BMI 30+, or 27+ with a qualifying condition — without the insurance gatekeeping. There's no prior authorization and no step therapy; a licensed clinician reviews your intake and history, and an eligibility decision often comes the same day. The trade-off is cost: you pay out of pocket, typically a few hundred dollars a month depending on the medication and program. Our program comparison and current pricing tracker lay out the options side by side.

Who Does Not Qualify

Some exclusions are absolute, regardless of BMI or diagnosis. Per FDA labeling, GLP-1 medications are contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and they should not be used during pregnancy. Clinicians also weigh relative cautions — a history of pancreatitis, severe gastroparesis, advanced kidney or liver disease, or an active eating disorder — case by case. The full eligibility reference covers these in detail, and our side-effects guide explains what monitoring looks like once you start.

What to Do Next

Start with the two-minute version: our GLP-1 eligibility quiz walks through the same screening questions a telehealth intake would — BMI, conditions, contraindications — and points you to the pathway that fits your situation. If you already know you meet the criteria, the practical next step is getting a prescription through your doctor or a telehealth program.

The bottom line for 2026: the clinical bar is lower than most people assume, the list of qualifying indications keeps growing, and for the first time even Medicare has a weight-management pathway. If you checked this question a year or two ago and hit a wall, the answer may have changed.

FAQ: Quick Answers

What BMI do you need to qualify for a GLP-1?

For the weight-management indication: BMI 30 or higher, or BMI 27 or higher plus at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. A 5'6" person crosses BMI 30 at about 186 pounds and BMI 27 at about 167 pounds.

Can I qualify without a BMI of 30?

Yes, through several pathways: BMI 27–29.9 with a weight-related condition; type 2 diabetes at any BMI; moderate-to-severe obstructive sleep apnea with obesity (Zepbound); or established cardiovascular disease with overweight or obesity (Wegovy).

Does Medicare cover GLP-1s for weight loss in 2026?

Partially, and this is new. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain GLP-1 medications for a $50 monthly copay — aimed at people using a GLP-1 for weight management who don't have a diagnosis Part D already covers.

Who should not take a GLP-1?

People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, and anyone who is pregnant. A history of pancreatitis, severe gastroparesis, or an active eating disorder warrants a careful risk-benefit conversation with a prescriber.

Do telehealth programs use different eligibility rules?

The clinical criteria are generally the same FDA thresholds. What differs is the process: self-pay telehealth skips prior authorization and step therapy, so decisions often come the same day rather than after weeks of insurance paperwork.

Related Articles

• Am I Eligible for GLP-1 Medications? The Full Screening Reference
• Take the 2-Minute GLP-1 Eligibility Quiz
• Does Insurance Cover GLP-1s? Coverage & Appeals Guide
• How to Get a GLP-1 Prescription

References

• FDA Prescribing Information: Wegovy (semaglutide) injection. Novo Nordisk. — Adult indication criteria (BMI ≥30, or ≥27 with at least one weight-related comorbid condition), pediatric indication (ages 12+), and contraindications (MTC/MEN2, pregnancy). accessdata.fda.gov.
• U.S. FDA press announcement (March 8, 2024). "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." — Wegovy cardiovascular risk-reduction indication in adults with established cardiovascular disease and obesity or overweight.
• U.S. FDA press announcement (December 20, 2024). "FDA Approves First Medication for Obstructive Sleep Apnea." — Zepbound (tirzepatide) indication for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA studies.
• Centers for Medicare & Medicaid Services. "Medicare GLP-1 Bridge." cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge — Program dates (July 1, 2026 – December 31, 2027), $50 monthly copay, covered products, and beneficiary eligibility limits.
• KFF (2026). "Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge." — Estimated eligible population and program cost projections.
• Wilding JPH, Batterham RL, Calanna S, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. — STEP 1: mean 14.9% body-weight reduction at 68 weeks.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 387(3):205-216. DOI: 10.1056/NEJMoa2206038. — SURMOUNT-1: up to 20.9% mean body-weight reduction at 72 weeks.